clopidogrel

Overview

Clopidogrel is an oral antiplatelet medication used to reduce platelet activation and aggregation. It is a prodrug that requires hepatic bioactivation, primarily through cytochrome P450 enzymes including cytochrome P450 family 2 subfamily C member 19 (CYP2C19), to generate its active metabolite. By inhibiting platelet P2Y12 signaling, clopidogrel is widely used in settings where prevention of arterial thrombosis is important, including after percutaneous coronary intervention (PCI) and in selected patients with ischemic cerebrovascular disease.

Its clinical effect can vary substantially between individuals because of differences in CYP2C19 function and because of drug interactions that alter CYP2C19-mediated activation. Recent research has therefore focused not only on clopidogrel’s antiplatelet efficacy, but also on factors that influence its onset, potency, and safety, including proton-pump inhibitor coadministration, CYP2C19 polymorphisms, and alternative formulations designed to accelerate bioactivation.

Focus of Latest Publications

Recent publications on clopidogrel have focused on its use within dual antiplatelet therapy and on factors that may modify its antiplatelet effect or clinical safety. In acute cerebrovascular disease, a randomized trial is evaluating whether combining clopidogrel-aspirin with immediate intensive statin therapy provides added benefit in patients with mild ischemic stroke or transient ischemic attack, building on prior evidence that each strategy may be beneficial on its own. Related stroke studies have also examined whether coadministration of clopidogrel with acid-suppressive agents affects outcomes, including comparisons of proton pump inhibitors and potassium-competitive acid blockers in patients with ischemic stroke.

Several studies have addressed clopidogrel in cardiovascular populations where drug response may be influenced by metabolism or comorbidity. In atrial fibrillation patients undergoing PCI and treated with oral anticoagulation plus clopidogrel, CYP2C19 polymorphism and platelet reactivity were assessed in relation to ischemic and bleeding outcomes. Loss-of-function CYP2C19 status was not significantly associated with the primary ischemic endpoint, but low platelet reactivity was associated with major bleeding, while high platelet reactivity showed a trend toward higher ischemic risk. Another cohort study compared cardiovascular outcomes among patients receiving clopidogrel with proton pump inhibitors classified by CYP2C19 inhibitory potency, reflecting ongoing concern that stronger CYP2C19 inhibition could reduce clopidogrel activation.

Clopidogrel has also been studied in high-risk hospitalized populations. In a global registry of patients with active cancer presenting with acute myocardial infarction, clopidogrel was the most frequently prescribed P2Y12 inhibitor. Compared with ticagrelor or prasugrel, clopidogrel use was associated with higher 5-year mortality, while major bleeding did not differ significantly between groups; the risk of AMI readmission was lower with clopidogrel than with ticagrelor. These findings were interpreted as supporting further evaluation of more potent P2Y12 inhibitors in this population.

Mechanistic and formulation research has also appeared. One study developed an intravenous micellar formulation designed to promote rapid hepatic bioactivation of clopidogrel for emergency antiplatelet therapy in acute coronary syndrome. The optimized formulation achieved faster liver delivery, a shorter time to peak active metabolite concentration, and more rapid antiplatelet effects than conventional oral administration. Together, these publications emphasize clopidogrel’s continued role in antiplatelet therapy while highlighting the importance of co-therapies, metabolic variability, and delivery strategies in determining its clinical performance.

Key Publications

• NEWJun Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial. (Neurology, 2026, PMID 42348803): "The aim of this study was to investigate the effect of combining clopidogrel-aspirin and immediate intensive statin in patients with acute mild ischemic stroke or transient ischemic attack (TIA)."
• Jun CYP2C19 Polymorphism and Platelet Aggregation-Associated Risks in Atrial Fibrillation Patients Undergoing PCI. (Clinical and translational science, 2026, PMID 42153956): "CYP2C19 genetic polymorphisms impact the antiplatelet effect of clopidogrel and associate with ischemic and bleeding risk in patients undergoing percutaneous coronary intervention (PCI)."
• Jun Utilization and Outcomes of Dual Antiplatelet Therapy in Patients With Active Cancer Presenting With Acute Myocardial Infarction: A Global Registry Study. (The American journal of cardiology, 2026, PMID 41936851): "Clopidogrel was the most frequently prescribed P2Y12 inhibitor (79%), followed by ticagrelor (16%) and prasugrel (4%)."
• May Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency. (Arteriosclerosis, thrombosis, and vascular biology, 2026, PMID 41783931): "Proton pump inhibitors (PPIs) may potentially reduce clopidogrel's antiplatelet effect and increase cardiovascular risk."
• May Increased Risk of Ischemic Events in Patients With Stroke Treated With Clopidogrel and a P-CAB or PPI. (Stroke, 2026, PMID 41766537): "This study evaluated the effectiveness and safety of P-CAB and PPI coadministered with clopidogrel in patients with ischemic stroke."
• May Structure-corona-function engineering of micelles enables rapid hepatic bioactivation of clopidogrel for emergency antiplatelet therapy. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41692042): "However, the oral dosage form of clopidogrel (CLP) commonly used in clinical practice shows a delayed onset due to gastrointestinal absorption, first-pass metabolism, and the requirement for hepatic cytochrome P450 (CYP450)-mediated bioactivation, which limits its applications in urgent scenarios and complicating post-PCI bleeding management."
• Dec Comparison of the Effect of Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists on Cardiovascular Outcomes on Clopidogrel-Based Dual Antiplatelet Therapy: A Nationwide Cohort Study. (The Annals of pharmacotherapy, 2025, PMID 41324390): "The cardiovascular safety of concomitant proton pump inhibitor (PPI) use with clopidogrel has been debated due to potential drug-drug interactions, although recent evidence suggests that these concerns may be less clinically significant."